Anti-hCD20-hIgA1

Human CD20 (Rituximab) antibody - Human IgA1

ABOUT

Monoclonal human IgA1 antibody against human CD20

Anti-hCD20-hIgA1 features the constant region of the human IgA1 isotype and the variable region of rituximab.

Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes.

Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity.

Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia.

Anti-hCD20-hIgA1 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with peptide M.

 

All products are for research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Isotype
hIgA1
kappa
Source
CHO cells
Purification
Affinity chromatography
Additional information

Provided azide-free and lyophilized.

CONTENTS

Contents

  • Product: 
    Anti-hCD20-hIgA1
  • Cat code: 
    hcd20-mab6
  • Quantity: 
    Custom size

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: Lyophilized product is stable for 1 year.

DOCUMENTS

Documents

Anti-hCD20-hIgA1

Technical Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

Contact us

Citations

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?